Shares of Five Prime Therapeutics (FPRX) is trading up 266% on positive cancer trial results which could be a potential breakthrough for stomach cancer.
The small cap biotherapeutics company announced on Thursday that it’s Phase 2 FIGHT trial which evaluated bemarituzumab in front line advanced gastric cancer and gastroesophageal junction cancer met all 3 pre-determined efficacy endpoints.
The therapeutic antibody targets FGFR2b+ tumors that are found in 30% of HER2-gastric cancers worldwide. According to the study, median progression-free survival improved from 7.4 months to 9.5 months with the median overall survival improved from 12,9 months to not reached. This means patients are still alive but has not been determined the media overall survival.
“These results bring us one step closer to the first potential targeted therapy for advanced gastric cancer in over a decade.”
Five Prime’s Chief Medical Officer Helen Collins
Collins added that bemarituzumab could have therapeutic potential in other forms of cancer, with FGFR2b+ being found in other cancers like squamous non-small cell lung cancer, triple negative breast cancer, ovarian cancer, pancreatic cancer and intrahepatic cholangiocarcinoma, according to the company.
Five Prime will evaluate all available data from its phase 2 trial and work with investigators to present results at an upcoming medical conference.
